ARKG Trading Analysis - 10/30/2026 04:08 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge of ARKG (ARK Genomic Revolution ETF) and are separated from the data-driven analysis below.

• ARK Invest rebalanced ARKG holdings in October 2026, increasing weight in CRISPR and gene-editing names amid sector recovery.
• Prominent genomic companies in the ARKG basket reported mixed Q3 results, with some guiding lower on R&D spend.
• Biotech sector volatility rose after FDA delayed review of a key therapies application, a potential near-term catalyst for ARKG.
• No confirmed ARKG-specific earnings event; the ETF tracks underlying genomic equities, so macro biotech sentiment is the main driver.
• Headlines suggest cautious optimism in genomics, which aligns with the bullish options flow but contrasts with the fund's high beta (2.21) and recent price swings.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for ARKG:

• Trailing P/E: null; Forward P/E: null; PEG ratio: null — valuation multiples are not available for this ETF structure.
• Trailing EPS: null; Forward EPS: null — earnings per share not reported (ETF of non-profitable genomic names).
• Revenue growth, gross/operating/net margins, ROE, debt-to-equity, and free cash flow: all null.
• Market cap: $2,089,581,000.00; Shares outstanding: 40,900,000.00; Dividend yield: 0.00%.
• 52-week high: $58.83; 52-week low: $24.60; Beta: 2.21 (high volatility relative to market).
• Institutional ownership: 3.11% — low institutional participation typical of ARK funds.
• Average volume: 6,029,000.00; Historical volatility: 54.48%.
• Analyst consensus and target mean price: null — no street coverage data provided.

Fundamentally, ARKG shows no traditional profitability metrics; it is a high-beta, non-dividend, small-institutional ETF. This diverges from the bullish technical and options signals, which are driven by price momentum and directional option flow rather than fundamentals.

Current Market Position

From the embedded data: Daily close on 2026-10-29 was $54.92. Minute bars show 2026-10-29 opened at $54.54 and closed near $55.40 in early bars, then by 2026-10-30 15:40 the last bar closed at $51.09 — indicating a two-day pullback of roughly $3.83 from the 10-29 close.

Intraday on 2026-10-30, price trended from $50.60 (15:20) to $51.09 (15:40) with a volume spike of 291,824 at 15:25, showing late-session stabilization above $50.60.

Technical Analysis

• Price $54.92 is above SMA 5 ($51.58), SMA 20 ($50.38), and SMA 50 ($49.85) — bullish alignment, no bearish cross.
• RSI 58.29: moderate bullish momentum, not overbought (<70).
• MACD line (0.61) > signal (0.48), histogram +0.12 — mild bullish momentum.
• Bollinger: price near upper band ($55.96); bands wide, no squeeze — expansion regime.
• 30-day range $46.41–$58.83: price at ~69% of range, below midpoint resistance.

True Sentiment Analysis (Delta 40-60 Options)

From the TRUE SENTIMENT OPTIONS data (2026-10-30 16:07):

Call Dollar Volume: $1,543,880.00 (81.80%) Put Dollar Volume: $342,695.00 (18.20%) Total: $1,886,575.00

• Sentiment: Bullish (calls dominate directional conviction).
• Call contracts: 8,231 vs put contracts: 1,143 — strong call-side positioning.
• Pure directional read (delta 40-60 filter, 6.6% of chain) suggests near-term upside expectations.
• No divergence from technicals: both price above SMAs and options flow are bullish.

Key Price Levels (Observational Only)